Category Archives: Events

Latest From Events

Bugs and Drugs: The Promising Microbiome Frontier

BIO_Investor_Forum_RGB_Large

Tuesday at the 2016 BIO Investor Forum wrapped up with a panel discussion on the exciting potential of microbiome research, a relatively new but fast growing field in biopharama. Although still in an early phase, there has been growing excitement over the possibility of bringing new microbiome-derived drugs and therapies to the market.  With promising signs such as the $121M National Microbiome Initiative commitment from the White House, we can anticipate that this field will Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Breakthrough at BIO 2017 in San Diego – Housing is Now Open

breakthrough_115x76

In June, BIO will host its 24th annual BIO International Convention. Since that very first meeting, we have seen extraordinary scientific breakthroughs happening across our industry. These breakthroughs have transformed how we treat patients, fuel our planet and feed a growing global population. As our industry has grown and evolved, so has the BIO International Convention. For more than two decades, the BIO Convention has been the place to learn about today’s breakthroughs and to Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , ,

A Neuroscience Fireside Chat with Ryan Watts at 2016 BIO Investor Forum

bif-logo

The 2106 BIO Investor Forum held a Fireside Chat with Ryan Watts, PhD on Tuesday, October 18 moderated by: Andrew Fein, Managing Director and Senior Healthcare Analyst, Research Division at H.C. Wainwright & Co., LLC. Rachel Lane, PhD, Equity Research, Biotechnology at H.C. Wainwright & Co., LLC Ryan Watts, PhD, is the current Chief Executive Officer at Denali Therapeutics Inc. in addition to being a co-founder and a member of the Board of Directors. Previously, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Does Big Company M&A Impact Small Company M&A?

bif-logo

Over the last few years, we have seen significant consolidation among the large drug manufacturers, with both franchise swapping and mergers of equals – but what is the impact on small biotechs? At the BIO Investor Forum, (held at the Westin St. Francis in San Francisco today), a panel session moderated by Matthew Hudes, Chief Executive Officer of bdlBiologx, set out to answer that very question. The panelists, all seasoned industry veterans, came from a Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

BIO Investor Forum Session on Advancing Immuno–Oncology

At the 2016 BIO Investor Forum, the first session held was titled “The Intersection of Inflammation and Immuno-Oncology: Risks and Opportunities.” Moderated by Michael King, Managing Director and Senior Research Analyst at JMP Securities, panelist included: Jay Venkatesan, MD, President & Director, Alpine Immune Sciences Pablo Cagnoni, MD, President & Chief Executive Officer, Tizona Therapeutics Alex Szidon, PhD, Executive Director, Business Development & Licensing; Head of West Coast Innovation Hub, Merck & Co. Inc. Paul Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,